Compare Aurora Cannabis Inc (ACB) vs Summit Therapeutics Inc (SMMT) Price & Performance

Aurora Cannabis (ACB) trades at $3.63, up 25.61% amid a hostile takeover bid from Curaleaf at a 45% premium. The stock shows mixed signals with a neutral technical outlook, while fundamentals reveal revenue growth to $343.29M in 2025 but a net income margin of -38.25% and negative ROE. Cash flow improved to a net positive $1.83M in 2025, though 2026 projections indicate renewed losses.

The takeover offer presents a near-term catalyst, but standalone risks persist including profitability challenges and competitive pressures. Analysts are cautious with a majority hold rating. Investors face a binary outcome: accept the premium bid or navigate ACB's volatile fundamentals.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.